The research advance on subtypes and relevant therapy of Parkinson's disease
10.16438/j.0513-4870.2022-0355
- VernacularTitle:帕金森病亚型及其治疗药物研究进展
- Author:
De-wen KONG
1
;
Li-da DU
2
;
Nan JIANG
1
,
3
;
Hai-guang YANG
1
;
Lian-hua FANG
1
;
Guan-hua DU
1
Author Information
1. Beijing Key Laboratory of Drug Targets Identification and Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2. Department of Surgery, University of Toronto, Toronto M5S1A8, Canada
3. School of Pharmacy, Henan University, Kaifeng 475004, China
- Publication Type:Research Article
- Keywords:
Parkinson's disease;
subtype;
biomarker;
prognosis;
pathology;
therapy
- From:
Acta Pharmaceutica Sinica
2022;57(8):2245-2252
- CountryChina
- Language:Chinese
-
Abstract:
Parkinson's disease (PD) is a progressive neurodegenerative disease with a high clinical heterogeneity. According to its motor symptoms, PD patients are divided into predominant tremor-dominant, postural instability and gait difficulty-dominant/akinetic-rigid and mixed subtypes. Different subtypes show different prognostic characteristics and different sensitivities to drugs. Therefore, the early classification of PD is of great significance for the treatment and prognosis of the disease. This paper reviews the clinical classification methods of different subtypes of PD, summarizes the latest biochemical markers and imaging features, and analyzed the differences in incidence, prognosis and pathological mechanism. The current clinical treatment drugs and methods have been preliminarily targeted for treatment based on PD classification, and there are many animal models of PD subtypes have been studied, providing new methods and strategies for mechanism research and preclinical pharmacodynamics evaluation of PD subtypes.
